Read the latest news and updates here from the Werling Comparative Oncology Research Center.
The Werling Comparative Oncology Research team is thrilled to announce the launch of a groundbreaking clinical trial aimed at advancing treatment options for dogs diagnosed with bladder cancer. Led by Dr. Debbie Knapp, a distinguished veterinary oncologist with decades of experience, this team has long been committed to exploring new frontiers in cancer research. Dr. Knapp's dedication has bridged the gap between veterinary and human oncology research, recognizing that canine bladder cancer closely resembles human bladder cancer. Her work not only advances treatment for our canine companions but also contributes valuable insights into combating bladder cancer in humans.
This trial focuses on a novel immunotherapy approach, utilizing a cPD-L1 monoclonal antibody (mAb) developed by Purdue scientists. Unlike traditional chemotherapy, this immunotherapy aims to harness the dog's immune system to target and attack cancer cells. Above, Lindsey Fourez, a Clinical Trials Nurse, administers the first intravenous infusion of the cPD-L1 mAb to Millie, the first patient to enroll in the trial. Millie will recieve her infusion biweekly, with the team closely monitoring her response to this innovative therapy.
Learn more about Millie's clinical trial
In 2024, the Werling Comparative Oncology Research Center (WCORC) welcomed three esteemed new faculty members to its ranks, strengthening its mission to provide cutting-edge cancer treatment and research for animals. These additions bring diverse expertise and an unwavering dedication to discovering improved therapies for animals affected by cancer.
The new hires include specialists with backgrounds in veterinary oncology, translational medicine, and clinical research, each bringing unique insights and skill sets to the Center's already robust team. Their joint efforts are expected to enhance Purdue's ongoing initiatives in cancer research, offering new possibilities for diagnosing, treating, and even preventing various forms of cancer in animals.
Dr. Marejka Shaevitz, a specialist in veterinary oncology with a focus on precision medicine, will be spearheading research projects aimed at tailoring treatments to the specific needs of each patient. Dr. Shawna Klahn, an expert in translational medicine, will focus on goals aimed at expediting the translation of discovery into tangible, marketable advances for the management of cancer in both humans and companion animals. Finally, Dr. Nick Dervisis, with extensive experience in clinical trials, will be leading initiatives to bring experimental treatments from lab to clinic, giving pets access to the latest advancements in cancer therapy.
The WCORC has long been a leader in the field, not only treating animals with compassion but also contributing valuable insights for human cancer research. By expanding its faculty, the Center reaffirms its commitment to excellence in veterinary oncology, promising hope to pets and pet owners alike who are affected by this devastating disease.
